Frontier AI companies like OpenAI and Anthropic have a narrow competitive moat—maybe one or two models ahead of open-source alternatives—and face a difficult choice: either compete on cheaper models with shrinking margins, or somehow lock down access through regulation. Neither path is straightforward, and their real survival depends on whether they can achieve recursive self-improvement before competitors catch up or customers stop paying.

• Frontier labs' advantage is temporary: they're only 1-2 models ahead of the competition, and that gap closes as talent and compute spread globally. Their moat depends partly on owning user data (code traces, conversations) that trains the next generation, but there's plenty of that data available elsewhere.
• Enterprise customers are already hitting their AI spending limits and demanding ROI. CFOs are questioning whether $200B+ in annual AI token spending actually translates to measurable business value, leading companies to restrict expensive frontier models and shift to cheaper alternatives.
• The labs' only real escape route is recursive self-improvement (RSI)—automating the research process so each model generates its successor faster. If that works, they leap ahead 20 generations instead of 2. If it doesn't, they're back to competing on commoditized inference margins.

OpenAI announced ChatGPT can now plug directly into Epic's EHR system, letting clinicians summarize charts and access patient data without switching apps. The author argues this is a major distribution win that absorbs the entire business model of thousands of healthtech startups—but it's not a technological breakthrough, and most specialized health AI companies will still die because they lack the workflow integration, liability ownership, and regulatory capabilities that actually matter.

• OpenAI's Epic integration directly threatens startups built on the pitch "AI that plugs into your EHR and saves time"—that exact value proposition is now baked into ChatGPT for free or cheap
• Distribution and deep workflow integration are the real competitive moats in healthcare AI, not better models or clever prompting; specialized companies with regulated write-back capabilities and liability ownership will survive, others won't
• OpenAI's 99.1% safety claim is marketing spin, not peer-reviewed validation, and the company still lacks the medical expertise and liability framework that established players like UpToDate have built over decades